Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure

S. Pongor, M. Brownlee, A. Cerami

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The marked propensity of insulin to self-associate into large aggregates causes significant mechanical problems in insulin delivery devices and may also stimulate production of a tissue-amyloid A precursor in some patients. Although conventionally prepared sulfated insulin (SI) resists aggregation, clinical application has been limited by major insulin bioactivity losses that occur during synthesis. To eliminate this problem, insulin sulfation was carried out in the organic solvent dimethylformamide in the presence of condensing agents such as N,N'-dicyclohexyl carbodiimide (DCC) and a sulfate donor. With this new procedure, the degree of sulfation could be controlled over an eightfold range by varying the amount of condensing agent. The bioactivity of these new SI derivatives varied between 78% and 87% of unmodified insulin. Insulin aggregation, induced by passage through a syringe and needle, did not occur with derivatives having two or more sulfate moieties per insulin molecule. Diffusion velocity studies using 'non-aggregated' insulin solutions demonstrated that aggregates were present in crystalline zinc and sodium porcine insulin. In contrast, SI having more than 0.5 mole sulfate per mole of insulin dialyzed as if it were predominantly in the monomeric form. Results from the studies described in this report now provide the means for selectively designing and preparing specific high-potency, non-aggregating insulins, which may be necessary for optimal use of current and future insulin delivery devices.

Original languageEnglish (US)
Pages (from-to)1087-1091
Number of pages5
JournalDiabetes
Volume32
Issue number12
StatePublished - 1983
Externally publishedYes

Fingerprint

Insulins
Insulin
Sulfates
Insulin, Regular, Pork
Serum Amyloid A Protein
Carbodiimides
Equipment and Supplies
Dimethylformamide
Syringes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Pongor, S., Brownlee, M., & Cerami, A. (1983). Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure. Diabetes, 32(12), 1087-1091.

Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure. / Pongor, S.; Brownlee, M.; Cerami, A.

In: Diabetes, Vol. 32, No. 12, 1983, p. 1087-1091.

Research output: Contribution to journalArticle

Pongor, S, Brownlee, M & Cerami, A 1983, 'Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure', Diabetes, vol. 32, no. 12, pp. 1087-1091.
Pongor, S. ; Brownlee, M. ; Cerami, A. / Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure. In: Diabetes. 1983 ; Vol. 32, No. 12. pp. 1087-1091.
@article{bcca7df9e1104d7f8c019bb777411ba0,
title = "Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure",
abstract = "The marked propensity of insulin to self-associate into large aggregates causes significant mechanical problems in insulin delivery devices and may also stimulate production of a tissue-amyloid A precursor in some patients. Although conventionally prepared sulfated insulin (SI) resists aggregation, clinical application has been limited by major insulin bioactivity losses that occur during synthesis. To eliminate this problem, insulin sulfation was carried out in the organic solvent dimethylformamide in the presence of condensing agents such as N,N'-dicyclohexyl carbodiimide (DCC) and a sulfate donor. With this new procedure, the degree of sulfation could be controlled over an eightfold range by varying the amount of condensing agent. The bioactivity of these new SI derivatives varied between 78{\%} and 87{\%} of unmodified insulin. Insulin aggregation, induced by passage through a syringe and needle, did not occur with derivatives having two or more sulfate moieties per insulin molecule. Diffusion velocity studies using 'non-aggregated' insulin solutions demonstrated that aggregates were present in crystalline zinc and sodium porcine insulin. In contrast, SI having more than 0.5 mole sulfate per mole of insulin dialyzed as if it were predominantly in the monomeric form. Results from the studies described in this report now provide the means for selectively designing and preparing specific high-potency, non-aggregating insulins, which may be necessary for optimal use of current and future insulin delivery devices.",
author = "S. Pongor and M. Brownlee and A. Cerami",
year = "1983",
language = "English (US)",
volume = "32",
pages = "1087--1091",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "12",

}

TY - JOUR

T1 - Preparation of high-potency, non-aggregating insulins using a novel sulfation procedure

AU - Pongor, S.

AU - Brownlee, M.

AU - Cerami, A.

PY - 1983

Y1 - 1983

N2 - The marked propensity of insulin to self-associate into large aggregates causes significant mechanical problems in insulin delivery devices and may also stimulate production of a tissue-amyloid A precursor in some patients. Although conventionally prepared sulfated insulin (SI) resists aggregation, clinical application has been limited by major insulin bioactivity losses that occur during synthesis. To eliminate this problem, insulin sulfation was carried out in the organic solvent dimethylformamide in the presence of condensing agents such as N,N'-dicyclohexyl carbodiimide (DCC) and a sulfate donor. With this new procedure, the degree of sulfation could be controlled over an eightfold range by varying the amount of condensing agent. The bioactivity of these new SI derivatives varied between 78% and 87% of unmodified insulin. Insulin aggregation, induced by passage through a syringe and needle, did not occur with derivatives having two or more sulfate moieties per insulin molecule. Diffusion velocity studies using 'non-aggregated' insulin solutions demonstrated that aggregates were present in crystalline zinc and sodium porcine insulin. In contrast, SI having more than 0.5 mole sulfate per mole of insulin dialyzed as if it were predominantly in the monomeric form. Results from the studies described in this report now provide the means for selectively designing and preparing specific high-potency, non-aggregating insulins, which may be necessary for optimal use of current and future insulin delivery devices.

AB - The marked propensity of insulin to self-associate into large aggregates causes significant mechanical problems in insulin delivery devices and may also stimulate production of a tissue-amyloid A precursor in some patients. Although conventionally prepared sulfated insulin (SI) resists aggregation, clinical application has been limited by major insulin bioactivity losses that occur during synthesis. To eliminate this problem, insulin sulfation was carried out in the organic solvent dimethylformamide in the presence of condensing agents such as N,N'-dicyclohexyl carbodiimide (DCC) and a sulfate donor. With this new procedure, the degree of sulfation could be controlled over an eightfold range by varying the amount of condensing agent. The bioactivity of these new SI derivatives varied between 78% and 87% of unmodified insulin. Insulin aggregation, induced by passage through a syringe and needle, did not occur with derivatives having two or more sulfate moieties per insulin molecule. Diffusion velocity studies using 'non-aggregated' insulin solutions demonstrated that aggregates were present in crystalline zinc and sodium porcine insulin. In contrast, SI having more than 0.5 mole sulfate per mole of insulin dialyzed as if it were predominantly in the monomeric form. Results from the studies described in this report now provide the means for selectively designing and preparing specific high-potency, non-aggregating insulins, which may be necessary for optimal use of current and future insulin delivery devices.

UR - http://www.scopus.com/inward/record.url?scp=0021041962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021041962&partnerID=8YFLogxK

M3 - Article

C2 - 6360757

AN - SCOPUS:0021041962

VL - 32

SP - 1087

EP - 1091

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 12

ER -